Verve Therapeutics Stock Today
| VERV Stock | USD 5.89 0.12 2.08% |
PerformanceWeak
| Odds Of DistressBelow Average
|
Verve Therapeutics is selling for under 5.89 as of the 20th of March 2025; that is 2.08 percent increase since the beginning of the trading day. The stock's lowest day price was 5.63. Verve Therapeutics has about a 44 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 88.8 M outstanding shares of which 14.02 M shares are at this time shorted by private and institutional investors with about 11.12 trading days to cover. More on Verve Therapeutics
Moving against Verve Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Verve Stock Highlights
| COO President | Andrew JD |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Verve Therapeutics (VERV) is traded on NASDAQ Exchange in USA. It is located in 201 Brookline Avenue, Cambridge, MA, United States, 02215 and employs 274 people. Verve Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 560.75 M. Verve Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 88.8 M outstanding shares of which 14.02 M shares are at this time shorted by private and institutional investors with about 11.12 trading days to cover.
Verve Therapeutics currently holds about 293.56 M in cash with (157.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9.
Check Verve Therapeutics Probability Of Bankruptcy
Ownership AllocationVerve Therapeutics shows a total of 88.8 Million outstanding shares. The majority of Verve Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Verve Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Verve Therapeutics. Please pay attention to any change in the institutional holdings of Verve Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Verve Ownership Details
Verve Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Verve Therapeutics market risk premium is the additional return an investor will receive from holding Verve Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0391 | |||
| Jensen Alpha | 0.2444 | |||
| Total Risk Alpha | 0.6558 | |||
| Sortino Ratio | 0.0525 |
Verve Stock Against Markets
Verve Therapeutics Corporate Management
| Jennifer Robinson | Vice Communications | Profile | |
| Kaitlin Duffy | Executive Resources | Profile | |
| Troy Lister | Chief Officer | Profile | |
| MD MPH | CoFounder Advisor | Profile | |
| Joan MBA | Chief Officer | Profile | |
| FACC MD | CoFounder | Profile |
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.